Seller record · Telehealth service

Meto

Fails 4 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The pages refer only to a 503A compounding pharmacy and licensed pharmacy partners. 3 more criteria also fail; see the table below.

At a glance

MetoTelehealth service

4/8criteria passed
Price
Compounded semaglutide or tirzepatide $199 a month, plus a $29 monthly membership and a $149 lab panel
Sells
compounded semaglutide, compounded tirzepatide, BPC-157, and 7 more
FDA letters
None on file
Visit MetoSee all eight dispositions

Telehealth service. Passes 4 of 8 criteria. Recorded against Standard v1.1.

A lab-first peptide telehealth service whose independent clinicians prescribe compounded peptide stacks and single peptides, including BPC-157, sermorelin, tesamorelin and compounded semaglutide or tirzepatide, after an intake and a blood panel, with a separately billed membership.

Operating entity Meto Health, Inc.

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSMeto's how it works page; Meto's terms
S2Prescription gatingPASSMeto's how it works page
S3Pharmacy identificationFAILMeto's protocols page; Meto's terms
S4Compounding disclosureFAILMeto's tesamorelin page; Meto's protocols page
S5Analytical documentationFAILMeto's about page; Meto's GLP-1 family page
S6Business addressFAILMeto's terms; Meto's privacy page; Meto's about page
S7Price disclosurePASSMeto's protocols page; Meto's membership page; Meto's GLP-1 family page
S8Enforcement statusPASSFDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA board-certified clinician reviews each patient's intake and lab results and approves or modifies the prescription, and the terms say every clinical decision is made by independent, licensed clinicians.Source: Meto's how it works page; Meto's terms.
S2PASSThe steps list a short medical intake first, and the page says any disqualifying finding is flagged before the patient pays anything, with no credit card required, followed by the lab panel and a clinician's review.Source: Meto's how it works page.
S3FAILNo filling pharmacy is named. The pages refer only to a 503A compounding pharmacy and licensed pharmacy partners.Source: Meto's protocols page; Meto's terms.
S4FAILThe tesamorelin page describes the compounded tesamorelin sold as FDA-approved for visceral fat reduction and answers yes to whether it is FDA-approved. The footer states that the compounded medications have not been approved by the FDA, which does not withdraw that claim.Source: Meto's tesamorelin page; Meto's protocols page.
S5FAILA certificate of analysis is offered only to members on request, and no certificate or lot report is published on any protocol, membership or about page.Source: Meto's about page; Meto's GLP-1 family page.
S6FAILNo postal address is printed in the footer, the terms, the privacy policy or on the about page, which give email contacts only.Source: Meto's terms; Meto's privacy page; Meto's about page.
S7PASSCompounded semaglutide or tirzepatide costs $199 a month, BPC-157 $85 a month, sermorelin $120 a month and tesamorelin $295 a month, with peptide stacks from $175 to $395 a month. A membership costs $29 a month and the lab panel $149 once, both billed apart from the medication.Source: Meto's protocols page; Meto's membership page; Meto's GLP-1 family page.
S8PASSNo FDA warning letter names Meto or Meto Health, Inc., and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, BPC-157, TB-500, sermorelin, tesamorelin, thymosin alpha-1, epitalon, GHK-Cu, NAD+.

Visit Meto

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.